Leave a clear path for the dialysis lifeline.

IN.PACT™ AV DCB:

  • Demonstrates 56% fewer reinterventions than PTA1
  • Slows the progression of restenosis
  • Minimizes the potential post-treatment limitations of stents
  • Extends the time between interventions by ~14.7 months2
  • Offers superior performance compared to PTA through 36 months2

Extend time between interventions.

AV access maintenance trials — target lesion primary patency†

IN.PACT™ AV DCB can extend the time between interventions by ~14.7 months2 – more than 5× longer than Lutonix​™* DCB.3


† Primary patency endpoints are defined differently; results are from different studies and may vary in a head-to-head comparison; charts are for illustration purposes only.

Risks may include: pain; hemorrhage; arterial or venous aneurysm/thrombosis, dissection, infection, perforation, or rupture; loss of permanent access; allergic/immunologic reaction; and death.

36-month data 

First and only DCB with superior, sustained results at 36 months2,3

Compared to PTA, the IN.PACT™ AV drug-coated balloon is the first and only DCB to show both superior and sustained results at 36 months in treating AV fistula lesions.

The highest reported primary patency of any DCB at 36 months

Results from separate trials comparing drug-coated balloons to standard PTA for AV fistula maintenance

Target lesion primary patency at 36 months†
IN.PACT™ AV DCB‡,2

Access circuit primary patency at 36 months† 
IN.PACT™ AV DCB§,2

No statistical difference in all-cause mortality between PTA and IN.PACT™ AV DCB at 36 months1

Target lesion primary patency at 24 months†
Lutonix™* DCB◊,3

Access circuit primary patency at 24 months† 
Lutonix™* DCB¶,3,8

† Primary patency rates are defined differently; results are from different studies and may vary in a head-to-head comparison; charts are for illustration purposes only.

Significantly reduces access circuit thrombosis2

Educational program

 The Use of DCB for AV Fistulas — CME (FPO)

Related links